

AKITA² APIXNEB NEBULIZER RECEIVES 510(k) CLEARANCE

Dublin/Ohio, Dec. 19, 2007 – Aerosol device specialist Activaero America, Inc. today announced that the AKITA² APIXNEB™ nebulizer system received 510(k) clearance by the US Food and Drug Administration (FDA). The 510(k) clearance allows Activaero to market the AKITA² APIXNEB nebulizer in the US.

Activaero's AKITA technology allows enhanced inhalation therapy by controlled breathing. Aerosolized drug is delivered at distinct intervals within the inspiratory cycle. The future goal of the AKITA technology is to enhance inhaled treatments in patients where the treatment safety and efficacy profile may be improved by drug targeting.

William C. Zimlich, CEO of Activaero America, Inc. said: "The 510(k) clearance of the AKITA² APIXNEB nebulizer is a major milestone for Activaero. It significantly facilitates the positioning of our AKITA technology as a highly valuable tool for pulmonary drug delivery."

Activaero entered into an exclusive joint development agreement with Talecris Biotherapeutics in 2006 for the use of the AKITA² APIXNEB inhalation system in the development of aerosolized alpha-1 antitrypsin therapy. "We congratulate Activaero on achieving this important milestone," said Steve Petteway, Senior Vice President, Research & Development. "We are hopeful this accomplishment will streamline the regulatory process for our aerosolized alpha-1 antitrypsin development program."

ABOUT AKITA² APIXNEB NEBULIZER

AKITA² is a world-wide protected intelligent nebulizer control unit that controls the breathing pattern of the patient during inspiration. With AKITA, the inhalation treatment can be tailored individually to each patient through Smart Card technology to improve reproducible dosage in the human lungs. The AKITA² APIXNEB contains the APIXNEB nebulizer handset made by PARI Pharma GmbH marketed as an exclusive product of Activaero for the AKITA² drug delivery system. The AKITA² APIXNEB system is available for license and marketing for use with specific drug compounds and formulations only.

ABOUT ACTIVAERO

Activaero is a drug delivery company specializing in highly efficient aerosol technology and inhalation systems. Activaero partners globally with leading pharmaceutical and biotechnology

companies to apply its inhalation platforms to pharmaceuticals that require critical dosage control. Activaero is privately held and has facilities in Dublin, Ohio and in Germany (Gauting/Munich and Gemuenden/Wohra).

ABOUT TALECRIS BIOTHERAPEUTICS

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, and hemostasis. Talecris is proudly building upon a 60-year legacy of innovation and a commitment to improving the lives of people who rely on its therapeutic products. With an emphasis on scientific inquiry and technological excellence, Talecris is expanding its current portfolio of products, programs, and services through its own world-class product development organization as well as through strategic initiatives that leverage its strengths with those of its partners. Talecris, which earned revenues exceeding \$1.1 billion in 2006, is headquartered in biotech hub Research Triangle Park, N.C., and employs more than 4,000 talented people worldwide. To learn more about Talecris and how our employees are making a difference in the lives of patients and the healthcare community, visit www.talecris.com.

CONTACT

Activaero America, Inc.
William C. Zimlich
P.O. Box 351
Dublin, OH 43017-9684, USA
Phone: 614 761 3555
Fax: 614 761 3505
E-Mail: zimlich@activaero.com

Activaero GmbH
Axel Fischer
Wohraer Str. 37
35285 Gemünden, Germany
Phone: +49 (0) 6453 64818-0
Fax: +49 (0) 6453 64818-22
E-Mail: fischer@activaero.de